blosozumab (LY2541546) / Eli Lilly, Transcenta - LARVOL DELTA

Newer Therapies for Osteoporosis: A Systematic Review. (PubMed, J Assoc Physicians India) - "Newer therapies for osteoporosis exhibited significant BMD gain and fracture risk reduction in men and PMO. The newer anabolic agents demonstrated greater efficacy than any of the previously available therapeutic options."

Journal • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Latest on Anabolic Agents for Osteoporosis Treatment. (PubMed, Endocrinol Metab Clin North Am) - "Their efficacies in preventing fragility fractures are widely demonstrated and their potential serious side effects were progressively downgraded, including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further data are warranted about their efficacy in glucocorticoids-induces osteoporosis and fracture healings."

Journal • Review • Cardiovascular • Musculoskeletal Diseases • Oncology • Orthopedics • Osteoporosis • Rheumatology

Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4 T cell interleukin-2 secretion. (PubMed, MAbs) - "Seven antibodies with known rates of immunogenicity (etanercept, emicizumab, abciximab, romosozumab, blosozumab, humanized anti-human A33 antibody, and bococizumab) induced responses in 1.9%, 3.8%, 6.4%, 10.0%, 29.2%, 43.8%, and 89.5% of donors, respectively. These data are comparable with ADA incidences in clinical settings. Our results show that this assay can contribute to the swift assessment and mechanistic understanding of the immunogenicity of therapeutic antibodies."

Journal • Preclinical • CD4 • IL2

Blosozumab in the treatment of postmenopausal women with osteoporosis: a systematic review and meta-analysis. (PubMed, Ann Palliat Med) - "The results suggested that blosozumab could be used as a target drug to improve BMD in postmenopausal women. This will provide a reference for the clinical treatment of postmenopausal women with osteoporosis."

Clinical • Journal • Retrospective data • Review • Osteoporosis • Rheumatology

TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: HJB (Hangzhou) Co., Ltd.

New P1 trial • Osteoporosis • Rheumatology

Sclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis. (PubMed, J Midlife Health) - "Monoclonal antibodies to SOST include romosozumab, blosozumab, and setrusumab. Its efficacy and safety have been established in trials. However, patients at high risk of cardiovascular or cerebrovascular events should not be prescribed romosozumab."

Journal • Review • Cardiovascular • Dyslipidemia • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • CTNNB1

Efficacy and safety of anti-sclerostin antibodies in the treatment of osteoporosis: A meta-analysis and systematic review. (PubMed, J Clin Densitom) - "Randomized controlled trials were searched from PubMed, EMBASE and Cochrane Central Register of Controlled Trails (CENTRAL) from their inception up to June 2021 by using Medical Subject Headings terms "anti-sclerostin antibody", "romosozumab", "blosozumab", "AMG 785″, "LY2541546", and "osteoporosis". Anti-sclerostin antibodies represent a valid theurapeutic option in the treatment of osteoporosis. Further studies with longer duration and follow-up are needed to confirm the results of this meta-analysis."

Journal • Retrospective data • Review • Osteoporosis • Rheumatology

Comparative efficacy between monoclonal antibodies and conventional drugs in postmenopausal women with osteoporosis: a network meta-analysis. (PubMed, Ann Palliat Med) - "Novel McAb treatments achieved better therapeutic effects in the treatment of postmenopausal osteoporosis (PMO), especially blosozumab. Further trials are needed to investigate and optimize the delivery strategy of McAbs."

Journal • Retrospective data • Osteoporosis • Rheumatology

Romosozumab: a novel bone anabolic treatment option for osteoporosis? (PubMed, Wien Med Wochenschr) - "In Japan, South Korea, Canada, Australia, and the USA, osteoporosis patients at a high risk of fracture may already be treated with romosozumab (Evenity). Approval in the European Union was granted by 2019-12-12."

Journal • Breast Cancer • Cardiovascular • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • Solid Tumor

Pharmacometrics and Systems Pharmacology for Metabolic Bone Diseases. (PubMed, Br J Clin Pharmacol) - "This review provides an overview of several M&S approaches ranging from simple pharmacokinetic to integrated pharmacometric and systems pharmacology modeling. Examples are included to illustrate the use of these approaches during the development of several drugs for metabolic bone diseases such as bisphosphonates, denosumab, teriparatide and sclerostin inhibitors (romosozumab and blosozumab)."

Journal • Review • Metabolic Disorders • Oncology • Osteoporosis